Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Cocktail & Poster Display session

37P - NET-mediated radio-resistance in early-stage non-small cell lung cancer

Date

04 Oct 2023

Session

Cocktail & Poster Display session

Presenters

Malcolm Ryan

Citation

Annals of Oncology (2023) 8 (suppl_1_S5): 1-55. 10.1016/esmoop/esmoop101646

Authors

M.I. Ryan1, S. Milette1, F. Bourdeau2, S. Doré1, R. Rayes2, P. Fiset3, L.A. Walsh1, J. Spicer3

Author affiliations

  • 1 Goodman Cancer Institute - McGill University, H3A 1A3 - Montreal/CA
  • 2 The Research Institute of the McGill University Health Centre, H3H 2L9 - Montreal/CA
  • 3 McGill University Health Center The Montreal General Hospital, H3G 1A4 - Montreal/CA

Resources

This content is available to ESMO members and event participants.

Abstract 37P

Background

Early-stage non-small cell lung cancer (NSCLC) has a 5-year survival rate of 63%. Current standards of care include surgery in the form of lobectomy or resection and stereotactic ablative radiotherapy (SABR). However, the current limitation of SABR is the moderate rates of reoccurrence in patients receiving treatment. We hypothesize that Neutrophil Extracellular Traps (NETs) may play a role in radio-resistance by decreasing T cell infiltration and activation in the tumor microenvironment.

Methods

The SABR-Bridge cohort is comprised of patients eligible for surgery that instead received neoadjuvant SABR followed by surgery 3-6 months later due to the SARS-COV-2 Pandemic. This cohort provides the unique ability to analyze changes in the microenvironment in non-responders after radiation. In addition, we use an orthotopic model of NSCLC with LLC1 cells injected into the left lung of wildtype or PAD4KO mice. Mice were then irradiated on day 7 and the tumor microenvironment was characterized with spectral flow cytometry and immunofluorescence spectroscopy.

Results

Result show that irradiated PAD4KO mice had significant decrease in both tumor volume and burden in comparison to controls. Further PD1+ CD8+ T cell infiltration in irradiated PAD4KO mice was significantly increased in comparison to controls. Survival analysis demonstrated that irradiated PAD4KO mice the received subsequent immonotherapy treatment had significantly better OS in comparison to wildtype controls.

Conclusions

It can be concluded that NETs play a role in radio resistance through decreasing T cell infiltration in a NSCLC orthotopic setting. Further, in PAD4KO preclinical models, adjuvant immunotherapy was more effective conferring greater OS. Future implications include the use of DNase or PAD4i to potentially increase radiation induced T cell infiltration in the context of adjuvant immune checkpoint-blockade therapy (ICI) in patient settings.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

The authors.

Funding

CIHR.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.